Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
|
|
- Phoebe Lynch
- 5 years ago
- Views:
Transcription
1 Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018
2 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast Cancer (N9831 and NSABP B-31) Perez E A et al. JCO 2014;32:
3 Why do we need predictive biomarkers? Identify patients whose cancer is likely to be particularly sensitive to targeted therapy (and can be spared chemotherapy) Identify patients who are not likely to do well on standard HER2-directed therapy Rationally select between multiple second-generation anti-her2 agents Provide potential insight into potential mechanisms of resistance
4 TAILORx: chemotherapy not needed in patients with very low Oncotype RS Secondary Group RS <11 Assigned to Hormonal Therapy Only Distant Relapse Free Survival Invasive Disease Free Survival 5 Year Results 99.3% 93.8% Overall Survival 98.0% Adapted from: Sparano JA et al. NEJM 2015
5 Why do we need predictive biomarkers? Identify patients whose cancer is likely to be particularly sensitive to targeted therapy (and can be spared chemotherapy) Identify patients who are not likely to do well on standard HER2-directed therapy Rationally select between multiple second-generation anti-her2 agents Provide potential insight into potential mechanisms of resistance
6 Why do we need predictive biomarkers? Identify patients whose cancer is likely to be particularly sensitive to targeted therapy (and can be spared chemotherapy) Identify patients who are not likely to do well on standard HER2-directed therapy Rationally select between multiple second-generation anti-her2 agents Provide insight into potential mechanisms of resistance
7 HER2 signaling pathway (simplified) HER2 PI3K AKT Proliferation Adapted from Gluck, Clin Breast Cancer 2016
8 HER2 as a biomarker?
9 CALGB 9840: (paclitaxel ± trastuzumab): No benefit to trastuzumab in HER2-negative MBC Seidman et al, JCO 2008, 26,
10 B-47 Adjuvant Trastuzumab in Patients with Normal/Low HER2 Expression Breast Cancer N=3260 High Risk Primary Breast Cancer IHC 1+ or 2+ for HER2 FISH Negative (and HER2 copy number<4) Randomization Anthracycline/taxane chemotherapy Anthracycline/taxane chemotherapy +Trastuzumab x 1 yr
11 % Disease-Free San Antonio Breast Cancer Symposium, December 5-9, 2017 B-47: Invasive Disease-Free Survival ChemoRx ChemoRx+Trast HR 0.98 (95% CI ) P=0.90 Treatment N Events 5 year EFS % % No. at Risk ChemoRx ChemoRx+Trast Time Since Randomization (months) This presentation is the intellectual property of the presenter. Contact them at Lou.Fehrenbacher@kp.org for permission to reprint and/or distribute
12 Level of HER2 amplification associated with pcr in TAXHER01 and GETNA01 studies LA: low amplification (mean, 6-10 signals) HA: high amplification (mean, >10 signals/nuclei) Arnould et al, Clin Cancer Res 2007;13(21)
13 Level of HER2 mrna and protein associated with pcr in TRYPHAENA (Chemo + trastuzumab+pertuzumab; All arms pooled) *Biomarkers high vs. low with cut point at median value Schneeweiss et al. Breast Cancer Research 2014, 16:R73
14 HER2 FISH ratios are not associated with trastuzumab benefit (DFS) in NCCTG N9831 HER2/ CEP17 n HR 95% CI P NSABP-B-31: no significant association between HER2 copy number and benefit (P = 0.60) Perez et al. JCO 28:
15 HER2 FISH ratios are not associated with trastuzumab benefit (DFS) in HERA Dowsett et al. JCO 27:
16 Very high HER2 protein expression not associated with trastuzumab benefit (DFS) in FinHer Very high HER2 protein ( log H2T 2.1)* Moderate HER2 protein ( log H2T <2.1) *Log H2T =2.1 HER2 protein expression is 22-fold the median of HER2-negative cancers Joensuu et al. Annals of Oncology 22:
17 HER2 FISH ratios are not associated with trastuzumab benefit (DFS) in NCCTG N9831 HER2/ CEP17 n HR 95% CI P NSABP-B-31: no significant association between HER2 copy number and benefit (P = 0.60) Perez et al. JCO 28:
18 HER2 FISH ratios are not associated with trastuzumab benefit (DFS) in HERA Dowsett et al. JCO 27:
19 Baselga SABCS 20129; Cleopatra: Prognostic effects independent of treatment arm (both arms pooled)
20 Baselga SABCS 20129; Cleopatra: Prognostic effects independent of treatment arm (both arms pooled)
21 Biomarkers to predict benefit of T-DM1: Improved outcomes with high HER2 mrna levels Krop et al ASCO 2009, Burris, et al. JCO. 2011;
22 TH3RESA (T-DM1 vs Treatment of Physicians Choice): Increased Benefit of T-DM1 in Cancers with HER2 mrna Level? a Hazard ratios are based on unstratified analyses. Kim et al, Int. J. Cancer: 139, (2016
23 Proportion progression-free EMILIA Biomarker Analysis: PFS by HER2 mrna Level and Treatment Arm HER2 median mrna conc. ratio = 13.3 n Lap + Cap Median (months) n T-DM1 Median (months) Hazard ratio a 95% CI Median > Median No. at risk: Lap + Cap ( Median) Lap + Cap (> Median) T-DM1 ( Median) T-DM1 (> Median) Time (months) Lap + Cap ( Median) Lap + Cap (> Median) T-DM1 ( Median) T-DM1 (> Median) a Hazard ratios are based on unstratified analyses.
24 HER2 as biomarker HER2 levels (mrna, FISH, protein) are associated with higher pcr in neoadjuvant trials HER2 levels do not predict benefit of adjuvant trastuzumab Very high HER2 levels may predict be associated with resistance to adjuvant trastuzumab Needs further validation HER2 mrna levels are associated with response to T- DM1 in MBC
25 HER2 signaling pathway (simplified) HER2 PI3K AKT Proliferation Adapted from Gluck, Clin Breast Cancer 2016
26 PIK3CA mutations within HER2+ disease All patients N=1,324 23% HR+ 24% PIK3CA_MUT PIK3CA_WT HR- 22% TCGA Nature 2012; Ferrari et al. Nat Com 2015; Loibl et al. (adapted Annals Oncol from2016 A Prat SABCS 2016)
27 PIK3CA mutations are associated with reduced pcr rates in pooled analysis of neoadjuvant studies Loibl et al, Annals of Oncology 27: , 2016
28 PI3-KINASE
29 Alterations in the PI3K/PTEN pathway are not associated with resistance to trastuzumab in NSABP B-31 (8 year DFS) WT Hazard ratio: 0.51 MT Hazard ratio: 0.44 PTEN loss had no influence on trastuzumab benefit in N9831 Pogue et al, JCO 33:
30
31
32 Proportion surviving EMILIA Biomarker Analysis: OS by PIK3CA Mutation Status and Treatment Arm 1.0 Lap + Cap T-DM1 PIK3CA mutation status n Median (months) n Median (months) Hazard ratio a 95% CI Mutated NE Wild type NE No. at risk: Lap + Cap (Mutated) Lap + Cap (Wild type) T-DM1 (Mutated) T-DM1 (Wild type) a Hazard ratios are based on unstratified analyses NE, not estimable. Lap + Cap (PIK3CA mutated) Lap + Cap (PIK3CA wild type) T-DM1 (PIK3CA mutated) T-DM1 (PIK3CA wild type) Time (months)
33 TH3RESA Biomarker Analysis: PFS by PIK3CA mutation status and Treatment Arm a Hazard ratios are based on unstratified analyses. Kim et al, Int. J. Cancer: 139, (2016
34 PI3-kinase as biomarker Mutations in PIK3CA are associated with lower pcr across many in neoadjuvant trials of HER2-directed therapy PIK3CA mutations or PTEN loss do not predict benefit of adjuvant trastuzumab PIK3CA mutations do not predict benefit of T-DM1 or pertuzumab in HER2+ MBC
35 HER2 signaling pathway (simplified) HER2 PI3K AKT Proliferation Adapted from Gluck, Clin Breast Cancer 2016
36 HER2 signaling pathway: cross-talk with ER Estradiol HER2 PI3K ER P mtor AKT ER S6K ER ER Proliferation Adapted from Gluck, Clin Breast Cancer 2016
37 San Antonio Breast Cancer Symposium Cancer Therapy and Research Center at UT Health Science Center December 6 10, 2011 Hormone receptor status and pcr in NeoSphere pcr, % 95% CI 70 p= p= ER or PR positive ER and PR negative TH THP HP TP ER, estrogen receptor; PR, progesterone receptor Gianni L, et al. Lancet Oncol 2011 DOI: /S (11) H, trastuzumab; P, pertuzumab; T, docetaxel (study dosing: q3w x 4 cycles) Copyrights for this presentation are held by the author/presenter. Contact them at gianni.luca@hsr.it for permission to reprint and/or distribute
38 Effect of Hormone Receptor expression on trastuzumab benefit in B-31/N9831 Perez et al, JCO 22:
39 Effect of Hormone Receptor expression on trastuzumab benefit in BCIRG-006 Slamon D, N Engl J Med 2011;365:
40 Effect of Hormone Receptor expression and HER2 copy number on trastuzumab benefit in HERA Loi et al JAMA Oncol. 2016;2(8):1040
41 Nonlinear interaction between expression levels of ESR1 and ERBB2 and trastuzumab benefit in NSABP B-31. Green = high trastuzumab benefit (HR 0.28) Brown = moderate benefit (HR 0.60) Red = no benefit (HR 1.58) Pogue-Geile K L et al. JNCI J Natl Cancer Inst 2013;105:
42 APHINITY: Trial Design Presented By Gunter Von Minckwitz at 2017 ASCO Annual Meeting
43 Presented By Gunter Von Minckwitz at 2017 ASCO Annual Meeting
44 1:1 randomization 2-year follow-up for idfs 5-year follow-up for idfs 5 + year survival Neratinib Extended Study Design Part A Part B Part C HER2+ breast cancer (local) Prior adjuvant trastuzumab & chemotherapy Lymph node /+ or residual invasive disease after neoadjuvant therapy ER/PR + or Neratinib x 1 year 240mg/day Placebo x 1 year Primary endpoint: invasive disease-free survival (idfs) Secondary endpoints: DFS-DCIS, time to distant recurrence, distant DFS, CNS metastases, overall survival, safety Other analyses: biomarkers, health outcome assessment (FACT-B, EQ-5d) Stratified by: nodes 0, 1 3 vs 4+, ER/PR status, concurrent vs sequential trastuzumab
45 Disease-free survival (%) Primary Endpoint: Invasive DFS (ITT) % 95.6% 93.9% 91.6% P-value = HR (95% CI) = 0.67 ( ) Neratinib Placebo Months after randomization No. at risk Neratinib Placebo Chan et al, Lancet Oncology 2016
46 Disease-free survival (%) idfs centrally-confirmed HER2 positive & HR+ idfs centrally-confirmed HR+ and HER2+ (ITT) % 97.0% % 88.4% 8.6% ER-positive: HR (95% CI) = 0.25 ( ) ER-negative: HR (95% CI) = 0.96 ( HR+ and centrally confirmed HER2 positive 60 Events: Neratinib vs Placebo (10 vs 41) Events: Neratinib vs Placebo (23 vs 22) HR+: estrogen and/or progesterone positive 50 Neratinib Placebo Months after randomization No. at risk Neratinib Placebo Adapted from A Chan et al, ASCO Breast 2015
47 Estrogen receptor as biomarker ER+ HER2+ breast cancers have markedly lower rates of pcr than ER-negative HER2+ cancer ER status alone does NOT predict benefit of adjuvant trastuzumab or pertuzumab In cancers with lower levels of HER2 expression and high ER expression, there are some data to suggest lower benefit of trastuzumab Needs validation ER status may predict benefit of neratinib
48 Intrinsic subtype as a biomarker?
49 171 Protein/phospho- Protein Expression Intrinsic subtypes: HER2-enriched by PAM50 Among the different subtypes, the HER2-E is characterized by the highest expression of HER2/EGFR proteins and phospho(p)-her2/p-egfr. Thus, HER2+/HER2-E disease is likely to have the highest activation of the HER2/EGFR pathway. TCGA Nature 2012; N=403 Groups based on Protein Expression Protein Expression TCGA Nature 2012 TCGA Nature 2012 Adapted from A Prat SABCS 2016
50 pcr rate in the breast pcr rate in the breast HER2 enriched subtype has highest rate of pcr in HER2+ cancers treated with neoadjuvant anti- HER2-based chemotherapy 100% NeoALTTO (n=254) Fumagalli et al. JAMA Oncol % CALGB40601 (n=262) Carey et al. J Clin Oncol % 60% 40% 20% 0% 80% 60% 40% 20% 0% 59.4% HER2-E vs. 29.3% Others; p< % HER2-E vs. 36.8% Basal-like; p=0.011 Adapted from A Prat SABCS 2016
51 Intrinsic subtype does not predict trastuzumab benefit in NSABP-B31 HER2 Enriched Basel Luminal A Luminal B Pogue-Geile et al. JCO 33:
52 Intrinsic subtype does not predict trastuzumab benefit in NCCTG-N31 HER2 Enriched Luminal A/B Basel trastuzumab trastuzumab No trastuzumab No trastuzumab No trastuzumab trastuzumab Pogue-Geile et al. JCO 33:
53 Immune activation as a biomarker?
54 Tumor-infiltrating Lymphocytes are associated with pcr in cancers treated with HER2-directed therapy pcr rate NeoALTTO (n=387) Salgado et al. JAMA Oncol 2015 NeoSphere (n=243) Bianchini et al. Annals Oncol 2015 Adapted from A Prat SABCS 2016
55 CALGB 40601: Immune cell signatures are associated with pcr after treatment with HER2-directed therapy 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% P<0.001 IgG Signature High (n=109) Int (n=76) Low (n=80) 66% 61% 62% 53% 50% 39% 40% 39% 31% 24% 25% 17% Overall THL TH TL Activity of 5 immune signatures tested: B-cell T-cell CD8 T-cell IgG HER2+ immune cell All significantly associated with pcr Carey et al, ASCO 2014
56 Loi et al, ASCO 2012 Tumor infiltrating lymphocytes predict trastuzumab benefit in the FinHER trial Lymphocyte Predominant Breast Cancer Phenotype (LPBC) >50% infiltration
57 % RFS NCCTG-N31: No benefit of trastuzumab seen in lymphocyte predominant (LPBC) cancers ( 60% TILS) LPBC (N=94) non-lpbc (N=851) Chemo Chemo+trastu zumab Chemo+trastu zumab Chemo Log Rank = 0.22 Log Rank < Years from Randomization Perez et al, SABCS 2014 Abstract S1-06
58 Immune signature predicts benefit of adjuvant trastuzumab in N9831 Not immune signature enriched Immune signature enriched Interaction term P <.001 Perez E et al. JCO :701
59 This presentation is the intellectual property of the author/presenter. Contact him at for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium, December 5-9, 2017 Immune signature predicts benefit of the addition of lapatinib IgG Low IgG High Krop et al SABCS 2017
60 Summary Predictive biomarkers to allow tailoring HER2-directed therapy to the appropriate patients are needed Multiple biomarkers are associated with rates of pcr in HER2+ cancers treated with HER2-directed therapy HER2 levels (mrna, FISH, protein); Higher pcr PI3-kinase (PIK3CA) mutation; Lower pcr ER positivity; Lower pcr HER2 enriched subtype; Higher pcr However, none of these biomarkers predict benefit of trastuzumab in adjuvant setting 60
61 What explains the difference in biomarker effects between the adjuvant and neoadjuvant settings? In most cases, all patients in neoadjuvant trials received at least one HER2-directed agent Thus generally evaluating prognostic effects of marker, not predictive effect 61
62 What explains the difference in biomarker effects between the adjuvant and neoadjuvant settings? Concurrent endocrine therapy in adjuvant setting Treatment effects on micrometastatic disease may differ from that of the primary cancer Different tumor microenvironment Immunomodulatory effects may differ in location and timeframe 62
63 Summary (2) Markers of immune activation (TILS and immune signatures) are associated with higher rates of pcr These immune markers also are associated with increased benefit from trastuzumab Perez data from N9831 is exception If further validated, immune activation markers could identify patients who are candidates for de-escalation approaches. 63
64 Thank You
Treatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationBiomarker research in HER2 positive breast cancer : a journey into the desert
WIN 9th Symposium 2017 Expediting Global Innovation in Precision Cancer Medicine Paris, June 26 & 27, 2017 Biomarker research in HER2 positive breast cancer : a journey into the desert Martine J. Piccart-Gebhart,
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationMalattia HER-2 positiva
Novità sul trattamento del carcinoma mammario Malattia HER-2 positiva Patrizia Vici Neoadjuvant - Adjuvant - Advanced Prognostic/Predictive factors..her-2 heterogeneity.. Neoadjuvant Phase II Pre-planned
More informationOptimizing anti-her-2 therapies for ABC Potential role of immunotherapy. Javier Cortes, Ramon y
Optimizing anti-her-2 therapies for ABC Potential role of immunotherapy Javier Cortes, Ramon y Cajal University Hospital, Madrid, Spain Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationHighlights. Padova,
Highlights P Pronzato Padova, 17.11.2012 Last 12 Months Main Meetings SABCS 2011 (San Antonio) EBCC 8 2012 (Wien) ASCO 2012 (Chicago) ESMO/ECCO 2012 (Wien) The Medical Oncology Job Risk Manager Strategy
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationWhat is the Next Goal for HER2 Targeted Therapy?
What is the Next Goal for HER2 Targeted Therapy? Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationCurrent and Future perspectives of HER2+ BC
2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More information(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationClaudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018
Claudio Zamagni Milano 16 giugno 2018 AIOM Post-ASCO BREAST CANCER HIGHLIGHTS ASCO 2018 (Neo)Adjuvant Advanced De-escalation ER+ve HER2 ve Node ve TAILORx HER2 +ve Persephone PerElisa PARPi in gbrcam HER2
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationersonalized adjuvant therapy based on clinica trials in breast cancer: dream or reality?
Global Breast Cancer Conference Jeju Island, Korea 20-22 April 2017 ersonalized adjuvant therapy based on clinica trials in breast cancer: dream or reality? Martine J. Piccart Gebhart, MD, PhD Institut
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer
Key Findings to Date in the Neoadjuvant Therapy of H2+ Breast Cancer Novel Preoperative Therapies for H2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationPresent and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationTreatment of Early Stage HER2-positive Breast Cancer
Treatment of Early Stage HER2-positive Breast Cancer 3 November 2012 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky Lexington, KY Molecular Portrait
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More information